Overview

Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis

Status:
Active, not recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

To assess the safety and feasibility of combined inhalational and intravenous amphotericin B therapy for the treatment of pulmonary mucormycosis. And compare the efficacy of combined therapy with that of intravenous amphotericin B alone.

Phase:

Phase 2

Details

Lead Sponsor:

Postgraduate Institute of Medical Education and Research

Treatments:

Amphotericin B
Deoxycholic Acid
Liposomal amphotericin B